Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study

@article{Aragona2009PsychopathologicalAC,
  title={Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study},
  author={Massimiliano Aragona and Emanuela Onesti and Valentina Tomassini and Antonella Conte and Shiva Gupta and Francesca Gilio and Patrizia Pantano and Carlo Pozzilli and Maurizio Inghilleri},
  journal={Clinical Neuropharmacology},
  year={2009},
  volume={32},
  pages={41-47}
}
Objectives: To study possible psychopathological symptoms and cognitive deficits, abuse induction, as well as general tolerability and effects on quality of life, fatigue and motor function in cannabis-naïve patients with multiple sclerosis (MS) treated with a free-dose cannabis plant extract (Sativex). Methods: In an 8-week, randomized, double-blind, placebo-controlled, parallel group crossover trial, 17 cannabis-naïve patients with MS were assessed at baseline and at the end of the cannabis… 

Effects of cannabis on cognitive function in patients with multiple sclerosis

TLDR
This cross-sectional study provides empirical evidence that prolonged use of inhaled or ingested street cannabis in patients with MS is associated with poorer performance on cognitive domains commonly affected in this population.

A Multicentre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Study of Effect of Long-Term Sativex Treatment on Cognition and Mood of Patients with Spasticity Due to Multiple Sclerosis

TLDR
Long-term treatment with Sativex was not associated with cognitive decline or significant changes in mood in this prone population sample and no new safety concerns were identified.

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

TLDR
Smoked cannabis was superior to placebo in symptom and pain reduction in participants with treatment-resistant spasticity, and future studies should examine whether different doses can result in similar beneficial effects with less cognitive impact.

Assessing the Neurophysiological Effects of Cannabinoids on Spasticity in Multiple Sclerosis

TLDR
Cannabinoids do not exert beneficial effects on MS-related spasticity through a direct action on the motor system as assessed by fMRI and electrophysiological methods.

Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis

TLDR
It is argued that all DMTs are likely to benefit cognition and that, if otherwise safe, SMTs with some empirical support may be attempted at the discretion of the treating clinician.

New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids

  • Paul F. Smith
  • Psychology
    Therapeutics and clinical risk management
  • 2010
TLDR
The available clinical trial data suggest that the adverse side effects associated with using CBMEs are generally mild, but there may be reason to be concerned about the use of therapeutic cannabinoids by adolescents, people predisposed to psychosis and pregnant women.

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis

TLDR
The pharmacological properties, clinical efficacy and tolerability of THC/CBD in MS patients is studied and adverse effects are usually mild or moderate and the low rate of drug discontinuation provides good evidence of long-term tolerability.
...

References

SHOWING 1-10 OF 44 REFERENCES

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

TLDR
These data provide limited evidence for a longer term treatment effect of cannabinoids in multiple sclerosis, and a long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS.

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

TLDR
It is concluded that long-term use of an oromucosal CBM (Sativex) maintains its effect in those patients who perceive initial benefit, and the precise nature and rate of risks with long- term use, especially epilepsy, will require larger and longer-term studies.

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

TLDR
A standardized Cannabis sativa plant extract might lower spasm frequency and increase mobility with tolerable side effects in MS patients with persistent spasticity not responding to other drugs.

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

TLDR
Dronabinol has a modest but clinically relevantanalgesic effect on central pain in patients with multiple sclerosis and on the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active treatment compared with placebo.

The perceived effects of smoked cannabis on patients with multiple sclerosis.

TLDR
The survey findings will aid in the design of a clinical trial of cannabis or cannabinoid administration to MS patients or to other patients with similar signs or symptoms.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

TLDR
CBM was generally well tolerated, although more patients on CBM than placebo reported dizziness, dry mouth, and somnolence, and Cognitive side effects were limited to long-term memory storage.

Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis

TLDR
It is concluded that this CBM may represent a useful new agent for treatment of the symptomatic relief of spasticity in MS.

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

TLDR
It is indicated that Δ-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses and warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders.

Cannabinoids in multiple sclerosis: urgent need for long term trials

TLDR
The CAMS study represents a substantial step forward, but not the final one, and the evidence for therapeutic efficacy in humans is not as yet convincing.

Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users

TLDR
It is demonstrated that oral Δ9-THC impairs episodic memory and learning in a dose-dependent manner whilst sparing perceptual priming and working memory.